Global Dysmenorrhea Treatment Market Study 2016-2026, by Segment (Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Hormonal, … …), by Market (Hospitals, Clinics, … …), by Company (Novartis AG (Switzerland), Merck (U.S), … …)
SKU ID :99ST-14585040 | Published Date: 06-Oct-2019 | No. of pages: 51Description
Summary
The global Dysmenorrhea Treatment market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
Hormonal
Combined Oral Contraceptive
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Hospitals
Clinics
Diagnostic Centers
Pharmaceutical Companies
Others
Novartis AG (Switzerland)
Merck (U.S)
Bayer Schering Pharma AG (Germany)
Abbott Healthcare (U.S)
Pfizer (U.S)
F. Hoffmann-La Roche Ltd (U.S)
Sanofi (U.S)
Taj Pharmaceuticals (India)
North America
Europe
Asia-Pacific
South America
Middle East & Africa
The global Dysmenorrhea Treatment market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
Hormonal
Combined Oral Contraceptive
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Hospitals
Clinics
Diagnostic Centers
Pharmaceutical Companies
Others
Company Coverage (Sales data, Main Products & Services etc.):
Novartis AG (Switzerland)
Merck (U.S)
Bayer Schering Pharma AG (Germany)
Abbott Healthcare (U.S)
Pfizer (U.S)
F. Hoffmann-La Roche Ltd (U.S)
Sanofi (U.S)
Taj Pharmaceuticals (India)
Major Region
MarketNorth America
Europe
Asia-Pacific
South America
Middle East & Africa
TOC
Tables & Figures
Companies
- PRICE
-
$1800$3600Buy Now